MovDisordV3, PascalFrancis, Corpus, bibRecord, 000964

Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment

Identifieur interne : 000964 ( PascalFrancis/Corpus ); précédent : 000963; suivant : 000965

Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment

Auteurs : Pauline Belujon ; Daniel J. Lodge ; Anthony A. Grace

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0413274

Descripteurs français

Pascal (Inist)
- Dyskinésie, Pathologie du système nerveux, Plasticité, Lévodopa, Traitement.

English descriptors

KwdEn :
- Dyskinesia, Levodopa, Nervous system diseases, Plasticity, Treatment.

Abstract

Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as _L-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic _L-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic _L-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to _L-dopa therapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment`
A11	`01`	`1`		`@1 BELUJON (Pauline)`
A11	`02`	`1`		`@1 LODGE (Daniel J.)`
A11	`03`	`1`		`@1 GRACE (Anthony A.)`
A14	`01`			`@1 Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh @2 Pittsburgh, PA @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A20				`@1 1568-1576`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000192608100060`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 10-0413274`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as _L-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic _L-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic _L-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to _L-dopa therapy.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Plasticité @5 09`
C03	`03`	`X`	`ENG`	`@0 Plasticity @5 09`
C03	`03`	`X`	`SPA`	`@0 Plasticidad @5 09`
C03	`04`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Traitement @5 11`
C03	`05`	`X`	`ENG`	`@0 Treatment @5 11`
C03	`05`	`X`	`SPA`	`@0 Tratamiento @5 11`
C07	`01`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 37`
C07	`01`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`01`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`02`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`02`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 41`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 42`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
N21				`@1 270`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0413274 INIST
ET :	Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment
AU :	BELUJON (Pauline); LODGE (Daniel J.); GRACE (Anthony A.)
AF :	Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh/Pittsburgh, PA/Etats-Unis (1 aut., 2 aut., 3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 11; Pp. 1568-1576; Bibl. 38 ref.
LA :	Anglais
EA :	Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as _L-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic _L-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic _L-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to _L-dopa therapy.
CC :	002B17; 002B02U01
FD :	Dyskinésie; Pathologie du système nerveux; Plasticité; Lévodopa; Traitement
FG :	Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Pathologie du système nerveux central
ED :	Dyskinesia; Nervous system diseases; Plasticity; Levodopa; Treatment
EG :	Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Central nervous system disease
SD :	Disquinesia; Sistema nervioso patología; Plasticidad; Levodopa; Tratamiento
LO :	INIST-20953.354000192608100060
ID :	10-0413274

Links to Exploration step

Pascal:10-0413274

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment</title>
<author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J." last="Lodge">Daniel J. Lodge</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A." last="Grace">Anthony A. Grace</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0413274</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0413274 INIST</idno>
<idno type="RBID">Pascal:10-0413274</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000964</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment</title>
<author><name sortKey="Belujon, Pauline" sort="Belujon, Pauline" uniqKey="Belujon P" first="Pauline" last="Belujon">Pauline Belujon</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lodge, Daniel J" sort="Lodge, Daniel J" uniqKey="Lodge D" first="Daniel J." last="Lodge">Daniel J. Lodge</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A." last="Grace">Anthony A. Grace</name>
<affiliation><inist:fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Plasticity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Plasticité</term>
<term>Lévodopa</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as <sub>L</sub>
-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic <sub>L</sub>
-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic <sub>L</sub>
-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to <sub>L</sub>
-dopa therapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BELUJON (Pauline)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LODGE (Daniel J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GRACE (Anthony A.)</s1>
</fA11>
<fA14 i1="01"><s1>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1568-1576</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000192608100060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0413274</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as <sub>L</sub>
-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic <sub>L</sub>
-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic <sub>L</sub>
-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to <sub>L</sub>
-dopa therapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Plasticité</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Plasticity</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Plasticidad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fN21><s1>270</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0413274 INIST</NO>
<ET>Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment</ET>
<AU>BELUJON (Pauline); LODGE (Daniel J.); GRACE (Anthony A.)</AU>
<AF>Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh/Pittsburgh, PA/Etats-Unis (1 aut., 2 aut., 3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 11; Pp. 1568-1576; Bibl. 38 ref.</SO>
<LA>Anglais</LA>
<EA>Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as <sub>L</sub>
-dopa-induced dyskinesia (LIDs). Studies suggest that LIDs may be associated with aberrant corticostriatal plasticity. Using in vivo extracellular recordings from identified Type I and Type II medium spiny striatal neurons, chronic <sub>L</sub>
-dopa treatment was found to produce abnormal corticostriatal information processing. Specifically, after chronic <sub>L</sub>
-dopa treatment in dopamine-depleted rats, there was a transition from a cortically evoked long-term depression (LTD) to a complementary but opposing form of plasticity, long-term potentiation, in Type II "indirect" pathway neurons. In contrast, LTD could still be induced in Type I neurons. Interestingly, the one parameter that correlated best with dyskinesias was the inability to de-depress established LTD in Type I medium spiny striatal neurons. Taken as a whole, we propose that the induction of LIDs is due, at least in part, to an aberrant induction of plasticity within the Type II indirect pathway neurons combined with an inability to de-depress established plastic responses in Type I neurons. Such information is critical for understanding the cellular mechanisms underlying one of the major caveats to <sub>L</sub>
-dopa therapy.</EA>
<CC>002B17; 002B02U01</CC>
<FD>Dyskinésie; Pathologie du   système nerveux; Plasticité; Lévodopa; Traitement</FD>
<FG>Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Pathologie du   système nerveux central</FG>
<ED>Dyskinesia; Nervous system diseases; Plasticity; Levodopa; Treatment</ED>
<EG>Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Central nervous system disease</EG>
<SD>Disquinesia; Sistema nervioso patología; Plasticidad; Levodopa; Tratamiento</SD>
<LO>INIST-20953.354000192608100060</LO>
<ID>10-0413274</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000964 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000964 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0413274
   |texte=   Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment

Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri